Base Editing Therapy Shows Durable Success Across Diverse Genetic Origins

Researchers from CorrectSequence Therapeutics, collaborating with multiple global institutions, successfully treated four patients from Nigeria, Laos, Malaysia, and Pakistan. These individuals, suffering from either sickle cell disease or transfusion-dependent β-thalassemia, achieved rapid hematopoietic recovery and sustained high levels of fetal hemoglobin. Notably, the cohort reached complete transfusion independence or freedom from vaso-occlusive crises without experiencing product-related adverse events or detectable off-target genetic mutations.

The clinical data highlights the precision of the tBE platform compared to traditional nuclease-based methods. By enabling base conversion without inducing DNA double-strand breaks, the technology avoids common risks like p53 activation and chromosomal rearrangements. In the case of the 21-year-old Nigerian patient, neutrophil and platelet engraftment occurred within 21 days, while hemoglobin levels stabilized significantly above baseline. Similar outcomes were observed in the three thalassemia patients, who maintained transfusion independence over a median follow-up of 17.5 months.

With more than 30 patients treated globally across China, Africa, and South Asia, the therapy is moving toward pivotal trials. Professor Chen Jia, founder of Correctseq, noted that the results validate the universal applicability of the tBE strategy. Beyond hemoglobinopathies, the company is now accelerating its pipeline to address metabolic and cardiovascular conditions, aiming for global regulatory submissions to expand the reach of these China-originated gene editing solutions.